Latest news with #Vision2026
Sydney Morning Herald
12 hours ago
- Business
- Sydney Morning Herald
Embattled Monash IVF moves to block defecting executive's move to rival
Monash IVF is seeking to hobble the defection of one of its top executives as it reels from a series of scandals, investigations and a plunging share price. The embattled fertility giant has launched action in the Supreme Court of Victoria in a bid to limit the work its departing chief operations officer, Dr Hamish Hamilton, is allowed to undertake in a senior role at its biggest rival, Virtus Health. The action comes as Monash was on Monday forced to respond to another please-explain order from the Australian stock exchange over claims it delayed informing the sharemarket of an embryo mix-up – the second such error and resulting notice issued to them this year. After decade in senior roles at Monash IVF, including the last five as its chief operating officer, Hamilton last week began duties as Virtus' chief operating officer and head of international business. His departure and the related court battle add to the public troubles for Monash IVF – including a $56 million class action involving more than 700 patients, two separate cases of women being implanted with a wrong embryo and the resignation of its chief executive officer – which have prompted an overhaul of the way Australia's reproductive technology sector is regulated. As investigations continue into how its patients were affected by its recent errors, Monash IVF on Monday focussed its attention on the court proceedings where it sought an injunction to prevent Hamilton undertaking aspects of his new role. Appearing for Monash IVF, Richard Dalton, KC, asked the court to impose limits on Hamilton's employment at Virtus until March 3, 2026, stating he had been the 'author' of Monash IVF's Vision 2026 strategic business plan and was well placed to act on commercial secrets. Monash IVF sought orders barring Hamilton from overseeing 'non-core IVF activities' such as day hospitals, ultrasounds and donor banks within Australia, and instead requested he be limited to overseeing Virtus' international donor operations. 'Dr Hamilton, as COO, was instrumental in that strategy and he knows what Monash IVF's plans are,' Dalton said.
The Age
16 hours ago
- Business
- The Age
Embattled Monash IVF moves to hobble defecting executive's move to rival
Monash IVF is seeking to hobble the defection of one of its top executives as it reels from a series of scandals, investigations and a plunging share price. The embattled fertility giant has launched action in the Supreme Court of Victoria in a bid to limit the work its departing chief operations officer, Dr Hamish Hamilton, is allowed to undertake in a senior role at its biggest rival, Virtus Health. The action comes as Monash was on Monday forced to respond to another please-explain order from the Australian stock exchange over claims it delayed informing the sharemarket of an embryo mix-up – the second such error and resulting notice issued to them this year. After decade in senior roles at Monash IVF, including the last five as its chief operating officer, Hamilton last week began duties as Virtus' chief operating officer and head of international business. His departure and the related court battle add to the public troubles for Monash IVF – including a $56 million class action involving more than 700 patients, two separate cases of women being implanted with a wrong embryo and the resignation of its chief executive officer – which have prompted an overhaul of the way Australia's reproductive technology sector is regulated. As investigations continue into how its patients were affected by its recent errors, Monash IVF on Monday focussed its attention on the court proceedings where it sought an injunction to prevent Hamilton undertaking aspects of his new role. Appearing for Monash IVF, Richard Dalton, KC, asked the court to impose limits on Hamilton's employment at Virtus until March 3, 2026, stating he had been the 'author' of Monash IVF's Vision 2026 strategic business plan and was well placed to act on commercial secrets. Monash IVF sought orders barring Hamilton from overseeing 'non-core IVF activities' such as day hospitals, ultrasounds and donor banks within Australia, and instead requested he be limited to overseeing Virtus' international donor operations. 'Dr Hamilton, as COO, was instrumental in that strategy and he knows what Monash IVF's plans are,' Dalton said.
Sydney Morning Herald
16 hours ago
- Business
- Sydney Morning Herald
Embattled Monash IVF moves to hobble defecting executive's move to rival
Monash IVF is seeking to hobble the defection of one of its top executives as it reels from a series of scandals, investigations and a plunging share price. The embattled fertility giant has launched action in the Supreme Court of Victoria in a bid to limit the work its departing chief operations officer, Dr Hamish Hamilton, is allowed to undertake in a senior role at its biggest rival, Virtus Health. The action comes as Monash was on Monday forced to respond to another please-explain order from the Australian stock exchange over claims it delayed informing the sharemarket of an embryo mix-up – the second such error and resulting notice issued to them this year. After decade in senior roles at Monash IVF, including the last five as its chief operating officer, Hamilton last week began duties as Virtus' chief operating officer and head of international business. His departure and the related court battle add to the public troubles for Monash IVF – including a $56 million class action involving more than 700 patients, two separate cases of women being implanted with a wrong embryo and the resignation of its chief executive officer – which have prompted an overhaul of the way Australia's reproductive technology sector is regulated. As investigations continue into how its patients were affected by its recent errors, Monash IVF on Monday focussed its attention on the court proceedings where it sought an injunction to prevent Hamilton undertaking aspects of his new role. Appearing for Monash IVF, Richard Dalton, KC, asked the court to impose limits on Hamilton's employment at Virtus until March 3, 2026, stating he had been the 'author' of Monash IVF's Vision 2026 strategic business plan and was well placed to act on commercial secrets. Monash IVF sought orders barring Hamilton from overseeing 'non-core IVF activities' such as day hospitals, ultrasounds and donor banks within Australia, and instead requested he be limited to overseeing Virtus' international donor operations. 'Dr Hamilton, as COO, was instrumental in that strategy and he knows what Monash IVF's plans are,' Dalton said.
Yahoo
03-03-2025
- Business
- Yahoo
Fresenius Continues Growth of Biosimilars Portfolio with the U.S. Availability of Otulfi® (ustekinumab-aauz)
The Fresenius ustekinumab biosimilar, Otulfi® was approved in September 2024 by the FDA for both subcutaneous and intravenous formulations, to treat the same conditions as the reference product Stelara® (ustekinumab) FDA Approval and U.S. launch are the result of partnership between Fresenius and Formycon AG Interchangeable designation forthcoming Otulfi® is fourth Fresenius biosimilar to launch in the U.S. and the company's third immunology biosimilar available in the U.S. Expansion of Biopharma platform fundamental to the success of Vision 2026 and #FutureFresenius strategies. LAKE ZURICH, Ill., March 03, 2025--(BUSINESS WIRE)--Fresenius Kabi, an operating company of Fresenius, and Formycon AG, a leading, independent developer of high-quality biosimilars, announced today that the ustekinumab biosimilar Otulfi® (ustekinumab-aauz) developed by Formycon AG, is now available in the United States. Otulfi® is an ustekinumab biosimilar for the reference product Stelara® (ustekinumab). Otulfi® is indicated for the treatment of moderately to severely active Crohn's disease and ulcerative colitis in adult patients, moderate to severely plaque psoriasis for adult patients and pediatric patients six years or older, who are candidates for phototherapy or systemic therapy, and active psoriatic arthritis in adults and pediatric patients six years or older. The development and commercialization of the ustekinumab biosimilar is the first biosimilar product launched in the U.S. from the partnership between Fresenius and Formycon AG. In February 2023, Fresenius and Formycon entered a global commercialization partnership for the ustekinumab biosimilar covering key global markets. The drug received FDA approval in September 2024. "The U.S. availability of Otulfi demonstrates our commitment to serving patients and clinicians. Through the expansion of our biopharma portfolio, we are able to do this globally and, in the U.S.," said Dr. Sang-Jin Pak, President Biopharma and member of the Fresenius Kabi Management Board. "In addition to approving Otulfi last year for all indications matching the reference product Stelara, the FDA has also granted a provisional determination of interchangeability for Otulfi." Otulfi will be available in the U.S. in the following presentations: a 45 mg/0.5 mL and 90 mg/mL single-dose prefilled syringe for injection and a 130 mg/26 mL (5 mg/mL) single dose vial for IV infusion. Otulfi in a 45 mg/0.5 mL single-dose vial for subcutaneous injection is expected to receive FDA approval in the first half of 2025. About Otulfi Otulfi (ustekinumab-aauz) is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23 which play an important role in inflammatory and immune responses. The FDA approval of Otulfi (ustekinumab-aauz) was based on a thorough evaluation of a comprehensive data package including analytical, pre-clinical, clinical and manufacturing data. Otulfi demonstrated comparable efficacy, safety, pharmacokinetics and immunogenicity to the reference drug Stelara® in patients with moderate to severe plaque psoriasis. Otulfi was approved for both subcutaneous and intravenous formulations which will offer a comprehensive, alternative treatment solution for health care professionals and patients treated with ustekinumab in the U.S. Otulfi (ustekinumab-aauz) is the fourth Fresenius biosimilar commercialized in the U.S., following the approvals and launches of Idacio® (adalimumab-aacf), Tyenne® (tocilizumab-aazg) and Stimufend® (pegfilgrastim-fpgk). Fresenius's growing pipeline of autoimmune and oncology biosimilars has several molecules in early and late-stage development. Indications OTULFI (ustekinumab-aauz) is an IL-12/23 antagonist indicated for treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy; active psoriatic arthritis; moderately to severely active Crohn's disease; moderately to severely active ulcerative colitis. Otulfi is also indicated for pediatric patients ≥6 years of age with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy and active psoriatic arthritis. IMPORTANT SAFETY INFORMATION OTULFI (ustekinumab-aauz) is contraindicated in patients with clinically significant hypersensitivity to ustekinumab products or to any of the excipients in OTULFI (ustekinumab-aauz). Infections Ustekinumab products may increase the risk of infections and reactivation of latent infections. Serious bacterial, mycobacterial, fungal, and viral infections were observed in patients receiving ustekinumab products. Serious infections requiring hospitalization, or otherwise clinically significant infections, reported in clinical trials included the following: Plaque psoriasis: diverticulitis, cellulitis, pneumonia, appendicitis, cholecystitis, sepsis, osteomyelitis, viral infections, gastroenteritis, urinary tract infections; Psoriatic arthritis: cholecystitis; Crohn's disease: anal abscess, gastroenteritis, ophthalmic herpes zoster, pneumonia, Listeria meningitis and Ulcerative colitis: gastroenteritis, ophthalmic herpes zoster, pneumonia, listeriosis. Avoid initiating treatment with OTULFI (ustekinumab-aauz) in patients with a clinically important active infection until the infection resolves or is adequately treated. Consider the risks and benefits of treatment prior to initiating use of OTULFI (ustekinumab-aauz) in patients with a chronic infection or a history of recurrent infection. Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur while on treatment with OTULFI (ustekinumab-aauz). Discontinue OTULFI (ustekinumab-aauz) for serious or clinically significant infections until the infection resolves or is adequately treated. Theoretical Risk for Vulnerability to Particular Infections Individuals genetically deficient in IL-12/IL-23 are particularly vulnerable to disseminated infections from mycobacteria (including nontuberculous, environmental mycobacteria), Salmonella (including nontyphi strains), and Bacillus Calmette-Guerin (BCG) vaccinations. Serious infections and fatal outcomes have been reported in such patients. It is not known whether patients with pharmacologic blockade of IL-12/IL-23 from treatment with ustekinumab products may be susceptible to these types of infections. Consider appropriate diagnostic testing (e.g., tissue culture, stool culture, as dictated by clinical circumstances). Pre-Treatment Evaluation of Tuberculosis (TB) Evaluate patients for TB prior to initiating treatment with OTULFI (ustekinumab-aauz). Avoid administering OTULFI (ustekinumab-aauz) to patients with active TB infection. Initiate treatment of latent TB before administering OTULFI (ustekinumab-aauz). Consider anti-TB therapy prior to initiation of OTULFI (ustekinumab-aauz) in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Closely monitor patients receiving OTULFI (ustekinumab-aauz) for signs and symptoms of active TB during and after treatment. Malignancies Ustekinumab products are immunosuppressants and may increase the risk of malignancy. Malignancies were reported among subjects who received ustekinumab in clinical trials. In rodent models, inhibition of IL-12/IL-23p40 increased the risk of malignancy. The safety of ustekinumab products has not been evaluated in patients who have a history of malignancy or who have a known malignancy. There have been reports of the rapid appearance of multiple cutaneous squamous cell carcinomas in patients receiving ustekinumab products who had pre-existing risk factors for developing non-melanoma skin cancer (NMSC). Monitor all patients receiving OTULFI (ustekinumab-aauz) for the appearance of NMSC. Closely follow patients >60 years of age, those with a medical history of prolonged immunosuppressant therapy, and those with a history PUVA treatment. Hypersensitivity Reactions Hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with ustekinumab products. If an anaphylactic or other clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue OTULFI (ustekinumab-aauz). Posterior Reversible Encephalopathy Syndrome (PRES) Two cases of posterior reversible encephalopathy syndrome (PRES), also known as Reversible Posterior Leukoencephalopathy Syndrome (RPLS), were reported in clinical trials. Cases have also been reported in postmarketing experience in patients with psoriasis, psoriatic arthritis and Crohn's disease. Clinical presentation included headaches, seizures, confusion, visual disturbances, and imaging changes consistent with PRES a few days to several months after initiating ustekinumab products. A few cases reported latency of a year or longer. Patients recovered with supportive care following withdrawal of ustekinumab. Monitor all patients treated with OTULFI (ustekinumab-aauz) for signs and symptoms of PRES. If PRES is suspected, promptly administer appropriate treatment and discontinue OTULFI (ustekinumab-aauz). Immunizations Prior to initiating therapy with OTULFI (ustekinumab-aauz), patients should receive all age-appropriate immunizations as recommended by current immunization guidelines. Patients being treated with OTULFI (ustekinumab-aauz) should not receive live vaccines. Avoid administering BCG vaccines during treatment with OTULFI (ustekinumab-aauz), or for one year prior to initiating treatment or one year following discontinuation of treatment. Caution is advised when administering live vaccines to household contacts of patients receiving OTULFI (ustekinumab-aauz) because of the potential risk for shedding from the household contact and transmission to patient. Non-live vaccinations received during a course of OTULFI (ustekinumab-aauz) may not elicit an immune response sufficient to prevent disease. Noninfectious Pneumonia Cases of interstitial pneumonia, eosinophilic pneumonia, and cryptogenic organizing pneumonia have been reported during post-approval use of ustekinumab products. Clinical presentations included cough, dyspnea, and interstitial infiltrates following one to three doses. Serious outcomes have included respiratory failure and prolonged hospitalization. Patients improved with discontinuation of therapy and in certain cases, administration of corticosteroids. If diagnosis is confirmed, discontinue OTULFI (ustekinumab-aauz) and institute appropriate treatment. Most Common Adverse Reactions The most common adverse reactions (≥3%) seen in patients treated with OTULFI (ustekinumab-aauz) are: Psoriasis: nasopharyngitis, upper respiratory tract infection, headache, fatigue; Crohn's disease, induction: vomiting; Crohn's disease, maintenance: nasopharyngitis, injection site erythema, vulvovaginal candidiasis/mycotic infection, bronchitis, pruritus, urinary tract infection, sinusitis; Ulcerative colitis, induction: nasopharyngitis and Ulcerative colitis, maintenance: nasopharyngitis, headache, abdominal pain, influenza, fever, diarrhea, sinusitis, fatigue, nausea. To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or Please click to see full Prescribing Information and Medication Guide for Otulfi® (ustekinumab-aauz) here. About Fresenius Kabi As a global health care company, Fresenius Kabi is Committed to Life. The company's products, technologies, and services are used for the therapy and care of patients with critical and chronic conditions. With more than 43,000 employees and present in more than 100 countries, Fresenius Kabi's expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients' nutritional status – notably as the only corporation offering both product groups. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is a global leader in supplying blood collection bags and devices, supporting blood banks and health care facilities worldwide. The company's I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to health care and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of almost 450 million patients annually. With Vision 2026, as part of the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of health care. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing health care solutions on a global scale. For more information, please visit and in the United States. About Formycon Formycon AG (FSE: FYB) is a leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials to approval by the regulatory authorities. For commercialization of its biosimilars, Formycon relies on strong, well-trusted and long-term partnerships worldwide. With FYB201/ranibizumab, Formycon already has a biosimilar on the market in Europe and the USA. Two further biosimilars, FYB202/ustekinumab and FYB203/aflibercept, have been approved by the FDA, EMA, and MHRA; FYB202 is also approved in Canada. Another four biosimilar candidates are currently in development. With its biosimilars, Formycon is making an important contribution to providing as many patients as possible with access to highly effective and affordable medicines. Formycon AG is headquartered in Munich, listed in the Prime Standard of the Frankfurt Stock Exchange: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY and is part of the SDAX and TecDAX selection indices. Further information can be found at: This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g., changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius Kabi does not undertake any responsibility to update the forward-looking statements in this release. Management Board: Pierluigi Antonelli (Chairman), Marc Crouton, Andreas Duenkel, Dr. Christian Hauer, Dr. Marc-Alexander Mahl, Dr. Sang-Jin PakChairman of the Supervisory Board: Michael SenRegistered Office: Bad Homburg, GermanyCommercial Register: Amtsgericht Bad Homburg - HRB 11654 Otulfi® (ustekinumab-aauz) is a trademark of Fresenius Kabi Deutschland GmbH in selected is a registered trademark of Johnson & (adalimumab-aacf) is a registered trademark of Fresenius Kabi Deutschland GmbH in selected (tocilizumab-aazg) is a registered trademark of Fresenius Kabi Deutschland GmbH in selected (pegfilgrastim-fpgk) is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries. View source version on Contacts Matt
